May-Aug 2016 Data Retrival from Pubmed: 11.11.2016 Contents
Total Page:16
File Type:pdf, Size:1020Kb
EUROPEAN SOCIETY OF ENDOCRINE SURGEONS ESES Review of Recently Published Literature Collection: T. Clerici, F. Triponez, S.M. Sadowski, K. Lorenz, M. Elwerr, J. Hein, L. Osmak, G. Franch-Arcas & C. Martinez-Santos Compilation and design: U. Beutner, [email protected] Affiliations see next page May-Aug 2016 Data retrival from Pubmed: 11.11.2016 Contents CTRL-click on category or count number jumps to the according page Publication count: SR/MA RCT CG Other Page Thyroid .............................. 5 .......... 2 ........... 2 ........ 96 ..................... 4 Parathyroids ....................... 0 .......... 1 ........... 1 ........ 26 ................... 45 Adrenals ............................. 4 .......... 0 ........... 2 ........ 19 ................... 57 NET ..................................... 0 .......... 0 ........... 0 ........ 20 ................... 68 General ............................... 0 .......... 0 ........... 0 .......... 0 ................... 76 SR: systematic review, MA: meta-analysis, RCT: randomized controlled trial, CG: consensus statement/guidelines Pubmed-ID: PubMed-Identifier (unique number for each Pubmed entry) blue underline: Hyperlink to PubMed entry or web site of publisher. Clicking on hyperlink opens the corresponding web site in browser (in Vista: CTRL-click). Collectors Thomas Clerici, MD Department of Surgery, Cantonal Hospital St. Gallen, St. Gallen, Switzerland Frédéric Triponez, MD Department of Thoracic and Endocrine Surgery, University Hospital of Geneva, Geneva, Switzerland Samira M Sadowski, MD Endocrine Oncology Branch, National Cancer Institute, NIH, Bethesda MD, USA Kerstin Lorenz, MD Malik Elwerr Janine Hein, MD Department of General-, Visceral-, and Vascular Surgery, Martin-Luther University of Halle- Wittenberg, Germany Liliana Osmak, MD Department of Endocrine Surgery, University Hospital Dijon, Dijon, France Guzmán Franch-Arcas, MD Endocrine Surgery, Department of General and Digestive Tract Surgery, University Hospital Salamanca, Salamanca, Spain Cristina Martinez-Santos, MD Endocrine Surgery, Hospital Costa del Sol Marbella, Málaga, Spain Compilation and Coordination Ulrich Beutner, Ph.D Department of Surgery, Cantonal Hospital St. Gallen, St. Gallen, Switzerland [email protected] ESES Review of Recently Published Literature 2016-2 Page 2 of 76 Journals covered Journal IF2014 Journal IF2014 Acta Cytol 1.562† J Bone Miner Res 6.832 Am J Kidney Dis 5.900 J Clin Endocrinol Metab 6.209 Am J Nephrol 2.669 J Clin Oncol 18.428 Am J Surg 2.291 J Endocrinol 3.718 Am Surgeon 0.818 J Endocrinol Invest 1.448 Ann Surg 8.327 J Nephrol 1.454 Ann Surg Oncol 3.930 J Nucl Med 6.160 ANZ J Surg 1.122 J Surg Oncol 3.244 Br J Surg 5.542 Lancet 45.217 Cancer 4.889 Langenbecks Arch Surg 2.191 Chirurg 0.574 Laryngoscope 2.144 Clin Endocrinol Oxf 3.457 N Engl J Med 55.873 Nat Rev Endocrinol Clin Nucl Med 3.931 13.281 (prev: Nat Clin Pract Endocrinol Metab) Nat Rev Clin Oncol Curr Opin Oncol 4.466 14.180 (prev: Nat Clin Pract Oncol) Endocr Relat Cancer 4.805 Nephrol Dial Transplant 3.577 Endocr Rev 21.059 Nephron Clin Pract 1.402 Eur Arch Otorhinolaryngol 1.545 Neuroendocrinology 4.373 Eur J Endorcrinol 4.069 Oncologist 4.865 Eur J Surg Oncol 3.009 Otolaryngol Head Neck Surg 2.020 Gland Surg --- Surg Clin North Am 1.879 Head Neck 2.641 Surg Endosc 3.256 Horm Metab Res 2.121 Surg Laparosc Endosc Percutan Tech 1.140 JAMA Otolaryngol Head Neck Surg 1.794 Surg Oncol 3.270 (prev: Arch Oto …..) JAMA Surg (prev: Arch Surg) 3.936 Surg Oncol Clin N Am 1.806 Int J Cancer 5.085 Surgery 3.380 J Am Coll Surg 5.122 Thyroid 4.493 J Am Soc Nephrol 9.343 Updates In Surgery --- J Bone Miner Metab 2.460 World J Surg 2.642 Journal names are links to the journal’s homepage!, IF2014: Impact factor 2014, †IF 2013, no IF for 2014 ESES Review of Recently Published Literature 2016-2 Page 3 of 76 Thyroid Meta-Analyses Factitious Graves' Disease Due to Biotin Immunoassay Interference-A Case and Review of the Literature. J Clin Endocrinol Metab, 101(9):3251-5. M. S. Elston, S. Sehgal, S. Du Toit, T. Yarndley and J. V. Conaglen. 2016. CONTEXT: Biotin (vitamin B7) is an essential co-factor for four carboxylases involved in fatty acid metabolism, leucine degradation, and gluconeogenesis. The recommended daily intake (RDI) of biotin is approximately 30 mug per day. Low-moderate dose biotin is a common component of multivitamin preparations, and high-dose biotin (10 000 times RDI) has been reported to improve clinical outcomes and quality of life in patients with progressive multiple sclerosis. Biotin is also a component of immunoassays, and supplementation may cause interference in both thyroid and non-thyroid immunoassays. OBJECTIVE: To assess whether biotin ingestion caused abnormal thyroid function tests (TFTs) in a patient through assay interference. DESIGN: We report a patient with biotin-associated abnormal TFTs and a systematic review of the literature. SETTING: A tertiary endocrine service in Hamilton, New Zealand. RESULTS: The patient had markedly abnormal TFTs that did not match the clinical context. After biotin cessation, TFTs normalized far more rapidly than possible given the half- life of T4, consistent with assay interference by biotin. Multiple other analytes also tested abnormal in the presence of biotin. CONCLUSION: Biotin ingested in moderate to high doses can cause immunoassay interference. Depending on the assay format, biotin interference can result in either falsely high or low values. Interference is not limited to thyroid tests and has the potential to affect a wide range of analytes. It is important for clinicians to be aware of this interaction to prevent misdiagnosis and inappropriate treatment. PubMed-ID: 27362288 http://dx.doi.org/10.1210/jc.2016-1971 Intraoperative Neuromonitoring in Thyroid Surgery: A Systematic Review. World J Surg, 40(8):2051-8. R. Malik and D. Linos. 2016. This study aimed to assess the efficacy of intraoperative neurophysiologic monitoring (IONM) in preventing recurrent laryngeal nerve palsy (RLNP) during thyroid surgery. When IONM results in false positives, it seeks to evaluate contributing factors. A systematic review was conducted gauging the predictive power of neuromonitoring in determining RLN function intraoperatively, its reductions of temporary and permanent RLNP rates, and surgeons' response to the technology. MEDLINE, EMBASE, and PubMed were searched for RLN monitoring in thyroid surgery following a set of inclusion/exclusion criteria. Seventeen studies comparing thyroid surgery with and without IONM were reviewed, including 30,926 patients. Selected studies were pooled to gage the predictive power. Mean specificity of IONM in identifying functional nerves was 90.24 % among 7366 nerves at risk (NAR). However, mean positive predictive power (PPP) was low, and both specificity and PPP varied substantially when stratified by risk levels. Among the pooled studies focusing on IONM efficacy-there were 44,575 NAR, of which (57.98 %) were operated on with IONM and 18,732 (42.02 %) without (control). The rates of overall RLNP per NAR were 3.18 and 3.83 % for the IONM group and control, respectively. There is no statistically significant difference between IONM and control, a conclusion supported by qualitative analysis from many individual studies. IONM is not recommended as the standard of care for thyroidectomies. Low PPP of IONM and complications associated with IONM-assisted thyroidectomies may be attributed to either the absence of a standardized negative-signal cutoff value or injury from intubation. PubMed-ID: 27329143 http://dx.doi.org/10.1007/s00268-016-3594-y Diagnostic accuracy of thyroid nodule growth to predict malignancy in thyroid nodules with benign cytology: systematic review and meta-analysis. Clin Endocrinol (Oxf), 85(1):122-31. N. Singh Ospina, S. Maraka, A. Espinosa DeYcaza, D. O'Keeffe, J. P. Brito, M. R. Gionfriddo, M. R. Castro, J. C. Morris, P. Erwin and V. M. Montori. 2016. BACKGROUND: Thyroid ultrasound to assess for nodular growth is commonly performed during the follow-up of patients with benign thyroid nodules, with the goal of identifying patients with a missed diagnosis of thyroid cancer. The objective of this study was to summarize the evidence regarding the diagnostic accuracy of growth during follow-up of benign thyroid nodules for thyroid cancer. METHODS: We searched multiple electronic databases using a search strategy designed by an experienced medical librarian from inception to March 2015. ESES Review of Recently Published Literature 2016-2 Page 4 of 76 Eligible studies included patients with benign thyroid nodules assessed for growth during follow-up and evaluated for thyroid cancer either by surgical histology or a repeat fine needle aspiration biopsy. Reviewers working independently and in duplicate recorded data and assessed each study. RESULTS: The seven eligible studies lacked safeguards against bias and generated results that were imprecise with wide confidence intervals and inconsistent across studies. This warrants very low confidence in these results. The odds of nodule growth in patients with thyroid cancer on histopathology over these odds in patients without thyroid cancer (diagnostic odds ratio) was 0.58 (95% CI: 0.26-1.3); the diagnostic odds ratio was 2.2 (95% CI: 0.26-18) when an abnormal repeat biopsy was the reference standard. CONCLUSION: The body of evidence linking nodule growth with thyroid cancer during the follow-up of benign nodules warrants very low confidence. In the era of high-value health care, the commonplace practice of following benign thyroid nodules with serial ultrasound assessment of growth to diagnose cancer can be questioned, calling for imminent evaluation. PubMed-ID: 26562828 http://dx.doi.org/10.1111/cen.12975 Systematic Review of Trends in the Incidence Rates of Thyroid Cancer. Thyroid, 26(11):1541-52. J. J. Wiltshire, T. M. Drake, L. Uttley and S. P. Balasubramanian. 2016. BACKGROUND: A large proportion of global increase in thyroid cancer (TC) incidence has been attributed to increased detection of papillary thyroid cancer (PTC). Nonetheless, some reports support a real increase in incidence.